Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Lane

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
The Journal of Biological Chemistry|February 18, 2017
A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factorKieron South, Marta O Freitas, David A Lane
Blood|July 5, 2005
Directing thrombinDavid A Lane, Helen Philippou, James A Huntington
Blood|February 22, 2014
Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWFChristopher J Lynch, David A Lane, Brenda M Luken
Blood|July 22, 2010
The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificityRens de Groot, David A Lane, James T B Crawley
Blood|January 8, 2015
The role of the ADAMTS13 cysteine-rich domain in VWF binding and proteolysisRens de Groot, David A Lane, James T B Crawley
Journal of Thrombosis and Haemostasis : JTH|August 30, 2019
Partial rescue of naturally occurring active site factor X variants through decreased inhibition by tissue factor pathway inhibitor and antithrombinJosefin Ahnström, Magdalena Gierula, Joseph Temenu, et al.
Peptides|June 14, 2005
Efficient isolation of peptide ligands for the endothelial cell protein C receptor (EPCR) using candidate receptor phage display biopanningStephen J White, Rachel E Simmonds, David A Lane, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 28, 2011
Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13)Yaozu Xiang, Rens de Groot, James T B Crawley, et al.
Plos One|November 30, 2017
A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET constructChristopher J Lynch, Adam D Cawte, Carolyn M Millar, et al.
Blood|February 24, 2009
Essential role of the disintegrin-like domain in ADAMTS13 functionRens de Groot, Ajoy Bardhan, Nalisha Ramroop, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
The Journal of Biological Chemistry|February 18, 2017
A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factorKieron South, Marta O Freitas, David A Lane
Blood|July 5, 2005
Directing thrombinDavid A Lane, Helen Philippou, James A Huntington
Blood|February 22, 2014
Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWFChristopher J Lynch, David A Lane, Brenda M Luken
Blood|July 22, 2010
The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificityRens de Groot, David A Lane, James T B Crawley
Blood|January 8, 2015
The role of the ADAMTS13 cysteine-rich domain in VWF binding and proteolysisRens de Groot, David A Lane, James T B Crawley
Journal of Thrombosis and Haemostasis : JTH|August 30, 2019
Partial rescue of naturally occurring active site factor X variants through decreased inhibition by tissue factor pathway inhibitor and antithrombinJosefin Ahnström, Magdalena Gierula, Joseph Temenu, et al.
Peptides|June 14, 2005
Efficient isolation of peptide ligands for the endothelial cell protein C receptor (EPCR) using candidate receptor phage display biopanningStephen J White, Rachel E Simmonds, David A Lane, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 28, 2011
Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13)Yaozu Xiang, Rens de Groot, James T B Crawley, et al.
Plos One|November 30, 2017
A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET constructChristopher J Lynch, Adam D Cawte, Carolyn M Millar, et al.
Blood|February 24, 2009
Essential role of the disintegrin-like domain in ADAMTS13 functionRens de Groot, Ajoy Bardhan, Nalisha Ramroop, et al.
Pageof 7